Evolus price to sales ratio EOLS

Market value divided by revenue over the last twelve months, since 2020.

Today, Oct 23, 2026: 1.5×
6-year median: 3.2×
Against its 6-year history: 9th; percentile: 0 is its lowest day, 100 its highest
6-year range: 0.9× to 12.4×
Peer median: 1.5×

Evolus' price to sales ratio is 1.5× as of Oct 23, 2026.

That is below its 6-year median of 3.2×, lower than on 91% of days in the last 6 years.

Over that time it ranged from 0.9× in Mar 2026 to 12.4× in Jun 2021.

The median for 10 large drugmakers of a similar size is 1.5×.

Price to sales ratio over time

Open the interactive chart, with overlays and comparisons

Year by year

Year	End of year	Low	High
2026 so far	1.5×	0.9×	1.9×
2025	1.6×	1.4×	3.8×
2024	2.8×	2.8×	4.7×
2023	3.3×	2.5×	4.5×
2022	3.0×	2.8×	6.5×
2021	4.2×	2.6×	12.4×
2020	2.0×	1.8×	4.1×

Against its peers

Companies in Drug Manufacturers - General nearest Evolus' size, closest first, today.

Company	Price to sales ratio
EOLSEvolus	1.5×
ARVNArvinas	1.5×
PBYIPuma Biotechnology	2.5×
IRWDIronwood Pharmaceuticals	1.5×
ZVRAZevra Therapeutics	4.3×
CRMDCorMedix	1.3×
COLLCollegium Pharmaceutical	0.9×
ABUSArbutus Biopharma	4.6×
NATRNatures Sunshine Products	0.4×
AMPHAmphastar Pharmaceuticals	1.5×
OMEROmeros	n/m
Peer median	1.5×

Where Evolus ranks

#29of 157Large drugmakers with the lowest price to sales ratio

What the price to sales ratio tells you

Market value divided by revenue over the last twelve months. Useful for companies with little or no profit yet, since sales are harder to make negative than earnings.

Ignores margins entirely. A software company at 10× sales with 30% margins can be cheaper than a grocer at 1× sales with 2% margins.

More on Evolus

Valuation data, not investment advice. Prices as of Oct 23, 2026. Reported figures come from the company's filings with the SEC.